Significant Ownership of Column Group IV GP, LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Column Group IV GP, LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ James Evangelista - James Evangelista, Attorney-in-Fact
Manager location
San Francisco, CA

Follow Filing Activity

Follow Column Group IV GP, LP and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Column Group IV GP, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SRZN Eikon Therapeutics, Inc. Common Stock, $0.0001 par value per share 12% $131,204,153 6,353,712 Tim Kutzkey 06 Feb 2026

Schedules 13D/G Reported by Column Group IV GP, LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .